Table 3 Biologic agent use in idiopathic and JIA uveitis
Drug | Idiopathic Uveitis | JIA Uveitis |
|---|---|---|
N = 92 (%) | N = 643 (%) | |
TNF inhibitor | 49 (53) | 353 (55) |
Adalimumab | 18 (20) | 196 (30) |
Certolizumab | 0 (0) | 1 (0.2) |
Etanercept | 0 (0) | 159 (25) |
Golimumab | 1 (1) | 3 (0.5) |
Infliximab | 36 (39) | 174 (27) |
Abatacept | 0 (0) | 23 (4) |
Anti-IL-1 | 0 (0) | 9 (1.5) |
Anakinra | 0 (0) | 7 (0.2) |
Rilonacept | 0 (0) | 1 (0.2) |
Canakinumab | 0 (0) | 1 (0.2) |
Rituximab | 0 (0) | 4 (0.5) |
Tocilizumab | 0 (0) | 4 (0.5) |